Rapport Therapeutics RAPP Ratios (2023-2026)

NASDAQ RAPP
$26.17 +0.10 (+0.36%)
As of: Nov 10, 2026 · 12:33 PM EST
Reported Financials

Rapport Therapeutics Quarterly Ratios

Periods 13 quarters
Latest Sep 2026

Rapport Therapeutics ratios data for the quarter ended Sep 2026. These financial ratios cover 13 quarters of results from Sep 2023 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

RatiosRatios Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Profitability
EBT Margin -99.29%
EBIT Margin -121.08%
EBITDA Margin -119.94%
Operating Margin -121.08%
Net Margin -99.29%
FCF Margin -65.74%
Efficiency
Assets AverageAssets Avg. 338.62M323.04M308.49M293.77M410.41M523.88M505.01M478.29M438.77M
Equity AverageEquity Avg. -11.28M-19.38M-32.63M148.63M330.00M314.27M295.63M274.67M387.56M498.14M478.08M447.22M407.06M
Asset Utilization RatioAsset Util. 0.040.05
Valuation
Price to SalesP/S 99.9180.25
Price to BookP/B 0.742.321.201.281.572.202.443.174.724.10
Enterprise Value -88.00M428.39M62.60M80.67M154.58M613.56M690.77M1,019.10M1,562.21M1,210.03M
Market Capitalization 248.10M749.09M367.90M366.07M414.98M1,126.56M1,181.27M1,495.90M1,998.29M1,605.03M
Return Ratios
Return on Sales [ROS]ROS -121.08%-767.58%-838.08%
Return on Capital Employed [ROCE]ROCE -22.42%-26.43%-31.12%-36.10%-27.80%-24.78%-25.09%-34.12%-40.05%
Return on Assets [ROA]ROA -19.03%-21.95%-25.84%-30.06%-23.81%-21.28%-21.24%-28.68%-34.29%
Return on Equity [ROE]ROE -37.43%-19.53%-22.57%-26.96%-32.15%-25.21%-22.38%-22.44%-30.67%-36.97%

Rapport Therapeutics Ratios API

Pull Rapport Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=RAPP&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY